Here you will find companies working on therapies that can alleviate acute COVID-19 disease.


We isolate and further develop natural microorganisms with immunomodulating properties and with gut protection properties to support the immune system  and to protect patient against secondary infections respectively.


Development of biomarker-controlled biotechnological therapeutics against sepsis, (adrecizumab, phase 2 completed); All patients who die from a Covid-19 infection have sepsis or a septic shock (70%)

AiCuris Anti-infective Cures

Evaluation of antiviral substances (incl. Re-purposing; perhaps participation in an EU consortium); Building up diagnostic capacity; Support for clinics and relief measures on site

APEIRON Biologics

Clinical trial of the drug candidate APN01 (rhACE2) to block the infection of cells by the novel virus SARS-CoV-2.


Advanced discussions with clinical centers in Europe to evaluate the human fusion protein Asunercept for the treatment of COVID-19 in two controlled Phase II clinical trials.

Atriva Therapeutics

Atriva has a new therapeutic agent ATR-002 in clinical development for severe influenza. In the current corona crisis, Atriva Therapeutics believes it is responsible to use the potential of its drug candidate ATR-002 and to push development against COVID-19. Laboratory tests with the new coronavirus SARS-CoV-2 are currently being carried out at three German universities to confirm the antiviral effectiveness of ATR-002. In parallel, the immunomodulating effects on the new virus are being researched. If these tests confirm the suspected effectiveness, ATR-002 can be used immediately in hospital-treated patients with COVID-19.

Berlin Cures (Berlin)

Berlin Cures prepares phase 2 clinical trial in COVID-19 patients with the non-cytotoxic virus inhibitor BC007 (aptamer)

Boehringer Ingelheim (Biberach)

Development of antibody therapy (with Yumab and other partners)

CORAT Therapeutics

The company develops innovative drugs for the treatment of infectious diseases. The lead product COR-101 is a fully human, SARS-CoV-2 neutralizing antibody that stops the spread of the virus in the body and can be used both for the treatment of people suffering from COVID-19 and for prophylactic treatment.

Cyano Biotech

Free supply of our globally unique natural product libraries and companies and university institutions with screening programs for antiviral corona active substances.

Eisbach Bio

We have started to develop new drugs against the helica domain of the coronavirus. We already have validated starting points for this from existing work.


SNIM RNA therapeutic agent for antibodies against SARS-CoV-2


Part of the NIH-led initiative Accelerating COVID-19 Therapeutic Interventions and Vaccines (“ACTIV”), a public-private partnership aiming to develop a framework for prioritising vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes, and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics

Joined “COVID R&D”, the global crowdsourcing initiative among top pharmaceutical company R&D leaders aimed at facilitating therapies and vaccines against COVID-19, where we will be sponsoring the pre-clinical repurposing group to channel candidate molecules from consortium members or external sources to COVID R&D


Development of an ACE2 antibody fusion protein (FYB207) to prevent infection of cells with SARS-CoV-2


Clone and Process Development: Support for the improvement of the Airway AT-100 yield and process support in production (Airway is testing approval AT-100 as a COVID-19 therapeutic agent, Airway AT-100 was developed in the Glycotope cell line); Medium term: IGa platform for SARS virus control (consortium in planning);

Immunic Therapeutics

Clinical trial with drug candidate IMU-838 in COVID-19 patients


Clinical trial with drug candidate IFX-1 in COVID-19

Lead Discovery Center

Long-term identification of viral and host cell-targeted inhibitors / therapeutics for coronavirus infections; - short-term approach to realignment; - antibody-like SARS-CoV-2 therapeutic; - Plan to invest in novel vaccination technology (one project will relate to SARS-CoV-2 vaccination).


Novartis donates millions of hydrochloroquine pills to controlled clinical trials which include Covid-19 sufferers

Pantherna Therapeutics GmbH

Development of an mRNA therapeutic to stabilize the endothelial barrier of the lung during inflammation.

Pfizer Pharma

Development of potential therapeutic agents, als vaccine development;


Attenuation or therapy of COVID-19 symptoms by stimulating the endogenous antiviral system.

Proteros biostructures

Therapeutic drug discovery approach to validated targets


Clinical trial of the drug tocilizumab for severe COVID-19 pneumonia


Test of the COPD candidate lonodelestat (POL6014) against the respiratory distress syndrome ARDS often associated with corona infections

Syntab Therapeutics

Development of an antiviral drug

TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

TRON's unique expertise and infrastructure of developing innovative drugs for better patient care are available.

Taconic Biosciences

Development of mouse models which can be used in research for the treatment of coronavirus (SARS-CoV-2).


Antibody development against hCOV-2; Drug candidates for therapy; Antibodies for diagnostics possible